ALK and neuroblastoma: These results warrant further exploration and validation in additional preclinical models to potentially support the development of clinical trials for patients with relapsed neuroblastoma, especially given recent evidence demonstrating the emergence of resistance mutations detected in ctDNA of patients treated with ALK-TKIs (21, 22).